HDV Biomarker Study
Part of Infections clinical trials.
This study looks at people with hepatitis D who are taking the medication bulevirtide. It aims to find biological markers that may help track the disease and guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 18 years
- You have a hepatitis D infection, with or without cirrhosis that is not causing serious symptoms
- You have been on bulevirtide 2 mg every day, as recommended by European guidelines
- You are also taking nucleoside analogues for hepatitis B and have very low or undetectable HBV DNA
- You have not had bulevirtide before or combined with peginterferon
- You have not had liver decompensation (like fluid in the belly or jaundice)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
This study uses a mobile diary app to track symptoms and quality of life for people living with hepatitis D infection. It may help researchers better understand the patient experience.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
Hear when a new HDV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.